Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENTI-202 in CD33 and/or FLT3 Expressing Malignancies
NCT06325748Phase 1Active, not recruiting
- Sponsor
- Senti Biosciences
- Start
- Apr 2024
- Primary completion
- Feb 2026
- Modality
- Gene Editing, Gene Silencing, CAR-NK Cells
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of SENTI-202 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Senti Biosciences. Primary endpoints: Safety and tolerability for dose determination of SENTI-202 at 2 years and Anti-cancer activity of SENTI-202 at 2 years. Started Apr 2024; status: active, not recruiting.
02
Drugs
SENTI-202
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06325748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06325748.